{"org_id": "T004435322", "org_name_cn": "成都先导药物开发股份有限公司", "org_short_name_cn": "成都先导", "org_name_en": "Hitgen Inc.", "org_short_name_en": "HitGen", "main_operation_business": "提供药物早期发现阶段的研发服务以及新药研发项目转让。", "operating_scope": "　　药物研发并提供技术咨询、技术转让、技术服务。(依法须经批准的项目，经相关部门批准后方可开展经营活动)", "district_encode": "510107", "org_cn_introduction": "成都先导药物开发股份有限公司主营业务是提供药物早期发现阶段的研发服务以及新药研发项目转让，主要服务有DEL筛选服务、DEL库定制服务、化学合成服务、新药研发项目转让、其他。公司在2016年荣获高新技术企业、2017年获得四川省先导化合物筛选工程技术研究中心。", "legal_representative": "李进", "general_manager": "李进", "secretary": "耿世伟", "established_date": 1329840000000, "reg_asset": 400680000.0, "staff_num": 458, "telephone": "86-28-8519-7385", "postcode": "610200", "fax": "86-28-8331-0298", "email": "investors@hitgen.com", "org_website": "www.hitgen.com", "reg_address_cn": "四川省成都市武侯区高新区科园南路88号1栋3层", "reg_address_en": "", "office_address_cn": "四川省成都市双流区天府国际生物城(双流区生物城中路二段18号)", "office_address_en": "", "currency_encode": "019001", "currency": "CNY", "listed_date": 1586966400000, "provincial_name": "四川省", "actual_controller": "李进 (28.68%)", "classi_name": "外资企业", "pre_name_cn": "成都先导药物开发有限公司", "chairman": "李进", "executives_nums": 14, "actual_issue_vol": 40680000.0, "issue_price": 20.52, "actual_rc_net_amt": 746011200.0, "pe_after_issuing": 110.77, "online_success_rate_of_issue": 0.04834612, "affiliate_industry": {"ind_code": "BK0044", "ind_name": "医疗器械服务"}}